Seikagaku reported FY 2Q20 orthopedic revenue of USD $31.3 million, -21.5% vs. 3Q19. The company’s ARTZ viscosupplement continued to take market share in Japan, but decreases in outpatient procedures due to COVID and drug price reductions offset those gains. While elective procedure recovery continued in the U.S., stocking orders fell compared to the prior year. Seikagaku’s sales in China decreased as well, due to curtailment of outpatient services in some areas of the country.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
2Q20
2Q19
$ Chg
% Chg
Orthobiologics
$31.3
$39.9
($8.6)
(21.5%)
1H20
1H19
$ Chg
% Chg
Orthobiologics
$59.5
$75.7
($16.2)
(21.4%)
Geographic Sales
2Q20
2Q19
$ Chg
% Chg
Domestic (Japan)
$11.5
$15.9
($4.4)
(27.6%)
International
$19.8
$24.0
($4.2)
(17.5%)
Total
$31.3
$39.9
($8.6)
(21.5%)
1H20
1H19
$ Chg
% Chg
Domestic (Japan)
$28.0
$32.4
($4.4)
(13.5%)
International
$31.5
$43.3
($11.8)
(27.2%)
Total
$59.5
$75.7
($16.2)
(21.4%)
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Seikagaku reported FY 2Q20 orthopedic revenue of USD $31.3 million, -21.5% vs. 3Q19. The company’s ARTZ viscosupplement continued to take market share in Japan, but decreases in outpatient procedures due to COVID and drug price reductions offset those gains. While elective procedure recovery continued in the U.S., stocking orders fell...
Seikagaku reported FY 2Q20 orthopedic revenue of USD $31.3 million, -21.5% vs. 3Q19. The company’s ARTZ viscosupplement continued to take market share in Japan, but decreases in outpatient procedures due to COVID and drug price reductions offset those gains. While elective procedure recovery continued in the U.S., stocking orders fell compared to the prior year. Seikagaku’s sales in China decreased as well, due to curtailment of outpatient services in some areas of the country.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
2Q20
2Q19
$ Chg
% Chg
Orthobiologics
$31.3
$39.9
($8.6)
(21.5%)
1H20
1H19
$ Chg
% Chg
Orthobiologics
$59.5
$75.7
($16.2)
(21.4%)
Geographic Sales
2Q20
2Q19
$ Chg
% Chg
Domestic (Japan)
$11.5
$15.9
($4.4)
(27.6%)
International
$19.8
$24.0
($4.2)
(17.5%)
Total
$31.3
$39.9
($8.6)
(21.5%)
1H20
1H19
$ Chg
% Chg
Domestic (Japan)
$28.0
$32.4
($4.4)
(13.5%)
International
$31.5
$43.3
($11.8)
(27.2%)
Total
$59.5
$75.7
($16.2)
(21.4%)
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
